Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HOOKVAC

Financiado

Cerrado

Developing and Testing a novel low cost effective HOOKworm VACcine to Control...

Developing and Testing a novel low cost effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infecti... ver más

31/03/2019

Academisch Medisch...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2019-03-31 No tenemos la información de la convocatoria

0% 78% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

Academisch Medisch Centrum A...

0.00€ | Lider

N.D. | Participante

Centre de Recherches Medical...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. This will be done in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas. Via a program of 48 months with 6 work packages, HOOKVAC will address 4 main objectives: (1) establish safety and immunogenicity of the vaccine candidate in an endemic population (2) improve the manufacturing process (3) provide clinical proof of concept (4) improve accessibility of the vaccine in endemic areas. The involvement of European SMEs in the project is a critical component to advancing a successful vaccine, and an integral part of adding private sector know-how and scientific expertise to the project. This will inspire other European SMEs to become more involved in public/private vaccine product development for neglected infectious diseases. By doing so, HOOKVAC will fuel a follow-up programme for further development of the vaccine towards into a licensed product.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores